The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money

Health Affairs

Volumn 30, Issue 7, 2011, Pages 1351-1357

  Shrank, William H ^a,d   Choudhry, Niteesh K ^b   Liberman, Joshua N ^c   Brennan, Troyen A ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEISINGER HEALTH SYSTEM   (United States)

^d CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CAPTOPRIL; CLONIDINE; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EXENDIN 4; FENOFIBRATE; FUROSEMIDE; GENERIC DRUG; GLIBENCLAMIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; METFORMIN; METOPROLOL; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; REPAGLINIDE; SIMVASTATIN; SITAGLIPTIN; SPIRONOLACTONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ARTICLE; CHRONIC DISEASE; CORONARY ARTERY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; HEALTH CARE COST; HYPERCHOLESTEROLEMIA; HYPERTENSION; QUALITY OF LIFE;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; FEMALE; HEALTH CARE REFORM; HUMANS; LONG-TERM CARE; MALE; UNITED STATES;

EID: 79960252970     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0431     Document Type: Article

References (23)

1. Hoffman C, Rice D, Sung HY. Persons with chronic conditions: their prevalence and costs. JAMA. 1996;276(18):1473-9.
2. Fireman B, Bartlett J, Selby J. Can disease management reduce health care costs by improving quality? Health Aff (Millwood). 2004; 3(6):63-75.
3. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358(7):661-3.
4. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008; 118(5):576-85.
5. Frank RG, Salkever DS (Harvard University; University of Maryland, Baltimore County). Generic entry and the pricing of pharmaceuticals [Internet]. Cambridge (MA): National Bureau of Economic Research; 1997 May [cited 2011 Jun 24]. (NBER Working Paper No. w5306). Abstract available from: http://ssrn.com/abstract=225370
6. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations [Internet]. Rockville (MD): FDA; [cited 2011 Jun 15]. Available from: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
7. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514-26.
8. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7): e46-215.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560-72.
10. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33:S11-61.
11. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
12. Centers for Medicare and Medicaid Services. Federal upper limits [Internet]. Baltimore (MD): CMS; [cited 2010 Feb 27]. Available from: http://www.cms.hhs.gov/Reimbursement/05_FederalUpper Limits.asp
13. Centers for Medicare and Medicaid Services. Medicaid prescription reimbursement information by state-quarter ending March 2009 [Internet]. Baltimore (MD): CMS; [cited 2011 Jun 15]. Available from: http://www.cms.hhs.gov/Reimbursement/Downloads/reimbursementchart1q2009.pdf
14. To access the Appendix, click on the Appendix link in the box to the right of the article online
15. Kaiser Family Foundation, Health Research and Educational Trust. Employer health benefits: 2010 annual survey [Internet]. Menlo Park (CA): KFF; 2010 [cited 2011 Feb 21]. Available from: http://ehbs.kff.org/pdf/2010/8085.pdf
16. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentivebased formularies on prescriptiondrug utilization and spending. N Engl J Med. 2003;349(23): 2224-32.
17. Carlton RI, Bramley TJ, Nightengale B, Conner TM, Zacker C. Review of outcomes associated with formulary restrictions: focus on step therapy. Am J Pharm Benefits. 2010 Feb:50-8.
18. Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010;29(7): 1383-90.
19. Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31-8.
20. Shrank WH, Cox E, Fischer MA, Mehta J, Choudhry NK. Patient perceptions of generic medications. Health Aff (Millwood). 2009;28(2): 546-56.
21. Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, Chang A, et al. The consequences of requesting "dispense as written." Am J Med. 2011;124(4):309-17.
22. National Partnership forWomen and Families. Patient charter for physician performance measurement, reporting, and tiering programs: ensuring transparency, fairness and independent review [Internet]. Washington (DC): The Partnership; [cited 2010 Feb 27]. Available from: http://www.rwjf.org/files/research/disclosurepatientcharter.pdf
23. Shrank WH, Chouhdry NK. Time to fill the donuts: health reform and Medicare Part D. N Engl J Med. 2011;364(7):598-601.